|
Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx). |
|
|
Stock and Other Ownership Interests - Perthera |
Honoraria - Caris Life Sciences; Celgene; Merrimack; Sirtex Medical |
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca/MedImmune; Caris Life Sciences; Celgene; Ignyta; Merck; Perthera; Rafael Pharmaceuticals; RenovoRx; Sirtex Medical |
Research Funding - ARMO BioSciences (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Curegenix (Inst); FibroGen (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Tesaro (Inst) |
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Caris Life Sciences; Perthera; Sirtex Medical |
|
|
Employment - AstraZeneca (I); Perthera |
Stock and Other Ownership Interests - Perthera |
Patents, Royalties, Other Intellectual Property - Named as an inventor on patents filed by Perthera, Inc. (as an employee) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Perthera |
Travel, Accommodations, Expenses - Perthera |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen; Novartis; Perthera |
Travel, Accommodations, Expenses - Halozyme |
|
|
Consulting or Advisory Role - HERON; Lilly |
|
|
Consulting or Advisory Role - Celgene; Five Prime Therapeutics; Ipsen; Perthera |
Speakers' Bureau - AstraZeneca; Celgene; Ipsen |
|
|
Honoraria - Foundation Medicine |
Consulting or Advisory Role - Perthera |
Research Funding - Agios (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Novartis (Inst); OncoMed (Inst) |
Travel, Accommodations, Expenses - Foundation Medicine |
|
|
Stock and Other Ownership Interests - Abbvie; Amgen; Gilead Sciences; Johnson & Johnson |
Consulting or Advisory Role - Abbvie; Cornerstone Pharmaceuticals; Gilead Sciences; Halozyme |
Research Funding - Aduro Biotech; Celgene; FibroGen; Immunomedics; OncoMed |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Perthera |
Consulting or Advisory Role - Perthera |
Research Funding - Teewinot Life Sciences (Inst) |
|
|
Leadership - Ceres Nanosciences; Perthera |
Stock and Other Ownership Interests - Avant Diagnostics; Ceres Nanosciences; Perthera |
Consulting or Advisory Role - Avant Diagnostics; AZGen; Ceres Nanosciences; Perthera |
Research Funding - Abbvie (Inst); Ceres Nanosciences (Inst); GlaxoSmithKline (Inst); Symphony Evolution (Inst) |
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty |
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera |